Axsome Therapeutics (NASDAQ:AXSM) Posts Earnings Results, Beats Estimates By $0.01 EPS

Axsome Therapeutics (NASDAQ:AXSM) issued its quarterly earnings results on Tuesday. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.01, Zacks reports. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%.

Axsome Therapeutics Trading Down 0.4 %

Shares of AXSM opened at $131.15 on Tuesday. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $134.18. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The firm has a 50 day simple moving average of $98.47 and a 200-day simple moving average of $93.68. The stock has a market cap of $6.36 billion, a price-to-earnings ratio of -20.08 and a beta of 1.05.

Analysts Set New Price Targets

A number of research firms have recently issued reports on AXSM. Robert W. Baird boosted their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Needham & Company LLC reissued a “buy” rating and issued a $133.00 price objective on shares of Axsome Therapeutics in a research note on Monday, February 10th. Royal Bank of Canada restated an “outperform” rating and issued a $139.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, January 29th. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Mizuho lifted their price objective on Axsome Therapeutics from $137.00 to $195.00 and gave the company an “outperform” rating in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $147.13.

Insider Buying and Selling at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 22.40% of the stock is owned by insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.